Evidence map›Paper›PMID 26690507›Full record

ReviewExpert review of medical devices2016

Evaluating the Role of mpMRI in Prostate Cancer Assessment.

Francesca V Mertan, Rose Berman, Kathryn Szajek, Peter A Pinto, Peter L Choyke, Baris Turkbey

Open access · greenAbstract readReview
In one paragraph

Review in Expert review of medical devices, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Francesca V Mertana Molecular Imaging Program , NCI, NIH , Bethesda , MD , USA.
Rose Bermana Molecular Imaging Program , NCI, NIH , Bethesda , MD , USA.
Kathryn Szajeka Molecular Imaging Program , NCI, NIH , Bethesda , MD , USA.
Peter A Pintoc Urologic Oncology Branch , NCI, NIH , Bethesda , MD , USA.
Peter L Choykea Molecular Imaging Program , NCI, NIH , Bethesda , MD , USA.
Baris Turkbeya Molecular Imaging Program , NCI, NIH , Bethesda , MD , USA.
National Institutes of Health · USMount St. Mary's University · US

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Prostate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2M
Intramural NIH HHS ZIA BC010655
6 · The paper itself

Abstract

Prostate cancer is the most common malignancy among American men. The role of multi-parametric MRI has recently gained more importance in detection of prostate cancer, its targeted biopsy, and focal therapy guidance. In this review, uses of multi-parametric MRI in prostate cancer assessment and treatment are discussed.

Indexed as

HumansImaging, Three-DimensionalMagnetic Resonance ImagingMaleNeoplasm Recurrence, LocalProstatic NeoplasmsReference Standardsbiopsyfocal therapyMRIPIRADSprostate cancer

Identifiers

PMID26690507
PMCPMC6364697
OpenAlexW2304374624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.